Clinical Trial

Avelumab Program Rollover Study

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.
Protocol Amendment History 45 amendments
This ClinicalTrials.gov record has been amended 45 times since 2019-01-22; most recent amendment 2026-06-26.
Status change: Recruiting → Active, Not Recruiting 2021-06-17
Status change: Not Yet Recruiting → Recruiting 2019-05-08
Trial Details
NCT Number NCT03815643
Lead Sponsor EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Solid Tumors
Enrollment 205 participants
Start Date 2019-03-22
Primary Completion 2026-08-21 (estimated)
Study Completion 2026-08-21 (estimated)
Updated on ClinicalTrials.gov 2026-06-29